Analysts’ Updated EPS Estimates for February, 22nd (A, AVGO, BARC, BLUE, DTE, FIE, FND, FPE, HEN3, IFNNY)

Analysts’ updated eps estimates for Friday, February 22nd:

Agilent Technologies (NYSE:A) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. Zacks Investment Research currently has $88.00 price target on the stock. According to Zacks, “Agilent reported strong fiscal first-quarter results on broad-based growth in all its product lines. The company also raised its guidance for full year 2019. The company’s expanding product portfolio, end-market strength and robust performance in Americas, China and Europe are key growth drivers. Moreover, the company’s decision to divest/wind up underperforming businesses is beneficial for its core operations. Further, the company’s focus on aligning investments towards more attractive growth avenues and innovative high-margin product launches are positive. Notably, shares of Agilent have outperformed the industry it belongs to over a year. However, macro weakness in some regions and unfavorable foreign exchange remain concerns. Also, higher expenses are making margin expansion difficult for Agilent.”

Broadcom (NASDAQ:AVGO) was downgraded by analysts at Cowen Inc from an outperform rating to a market perform rating. The firm currently has $280.00 price target on the stock.

Barclays (LON:BARC) was given a GBX 220 ($2.87) target price by analysts at Berenberg Bank. The firm currently has a buy rating on the stock.

bluebird bio (NASDAQ:BLUE) had its target price trimmed by Cantor Fitzgerald from $134.00 to $122.00. Cantor Fitzgerald currently has a neutral rating on the stock.

Deutsche Telekom (FRA:DTE) was given a €16.80 ($19.53) target price by analysts at Barclays PLC. The firm currently has a neutral rating on the stock.

Fielmann (FRA:FIE) had its neutral rating reaffirmed by analysts at DZ Bank AG.

Floor & Decor (NYSE:FND) had its price target raised by Telsey Advisory Group from $40.00 to $44.00. The firm currently has an outperform rating on the stock.

Fuchs Petrolub (FRA:FPE) was given a €37.00 ($43.02) target price by analysts at Hauck & Aufhaeuser. The firm currently has a neutral rating on the stock.

Henkel AG & Co KGaA (FRA:HEN3) was given a €86.00 ($100.00) target price by analysts at Royal Bank of Canada. The firm currently has a neutral rating on the stock.

Henkel AG & Co KGaA (FRA:HEN3) was given a €100.00 ($116.28) price target by analysts at Berenberg Bank. The firm currently has a neutral rating on the stock.

Cowen Inc assumed coverage on shares of Infineon Technologies (OTCMKTS:IFNNY). The firm issued an outperform rating on the stock.

Cowen Inc started coverage on shares of Lattice Semiconductor (NASDAQ:LSCC). Cowen Inc issued an outperform rating and a $15.00 price target on the stock.

Cowen Inc started coverage on shares of Microchip Technology (NASDAQ:MCHP). Cowen Inc issued a market perform rating and a $90.00 price target on the stock.

Cowen Inc started coverage on shares of Maxim Integrated Products (NASDAQ:MXIM). Cowen Inc issued a market perform rating and a $56.00 target price on the stock.

Cowen Inc initiated coverage on shares of ON Semiconductor (NASDAQ:ON). Cowen Inc issued an outperform rating on the stock.

Orange (EPA:ORA) was given a €18.30 ($21.28) price target by analysts at Goldman Sachs Group Inc. The firm currently has a buy rating on the stock.

Ovid Therapeutics (NASDAQ:OVID) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Ovid Therapeutics Inc. is a biopharmaceutical company. It engaged in developing therapies for patients with rare neurological disorders. The company’s product pipeline consists of OV101, is currently in development for the treatment of symptoms of Angelman syndrome and Fragile X syndrome. It also involved in developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies. Ovid Therapeutics Inc. is based in New York, United States. “

PagSeguro Digital (NYSE:PAGS) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “PagSeguro Digital Ltd. provides financial technology solutions and services for micro-merchants and small and medium-sized businesses primarily in Brazil and internationally. The Company offers multiple digital payment solutions, in-person payments via point of sales devices and prepaid cards services. PagSeguro Digital Ltd. is headquartered in Sao Paulo, Brazil. “

Progenics Pharmaceuticals (NASDAQ:PGNX) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Progenics Pharmaceuticals, Inc. is developing innovative medicines for oncology, with a pipeline that includes several product candidates in later-stage clinical development. Progenics’ first-in-class PSMA-targeted technology platform for prostate cancer includes an antibody drug conjugate therapeutic in a two-cohort phase 2 clinical trial and a small molecule imaging agent that has completed patient dosing in a phase 2 trial. Among other assets in its pipeline of targeted radiotherapy and molecular imaging compounds is Azedra(TM), an ultra-orphan radiotherapy candidate also in a phase 2 study under an SPA. Progenics’ first commercial product, Relistor(R) (methylnaltrexone bromide) for opioid-induced constipation, is partnered with and marketed by Salix Pharmaceuticals, Inc. “

IMPINJ (NASDAQ:PI) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. The firm currently has $22.00 price target on the stock. According to Zacks, “Impinj, Inc. is a provider of referral and information network radio frequency identification solutions to the retail, pharmaceutical, healthcare, food and beverage and other industries. The company’s products include Indy Reader Chips which consists of integrated radio chips and supporting SDKs; Monza Tag Chips, which deliver memory options and extended features to RFID tags and Speedway fixed RFID readers and antennas for RFID-based information. Impinj, Inc. is based in Seattle, Washington. “

Proteon Therapeutics (NASDAQ:PRTO) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Proteon Therapeutics Inc. is a biopharmaceutical company. The Company is developing pharmaceuticals to address the medical needs of patients with kidney and vascular diseases. It is developing PRT-201, a recombinant human elastase, applied in a single treatment to the external surface of arteries and veins during an open surgical procedure or an endovascular intervention. Proteon Therapeutics Inc. is headquartered in Waltham, Mass. “

Protagonist Therapeutics (NASDAQ:PTGX) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The Company’s initial lead product candidates consists of PTG-100 and PTG-200, which have the potential to transform the existing treatment paradigm for inflammatory bowel disease, a GI disease consisting primarily of ulcerative colitis and Crohn’s disease; PTG-300, an injectable hepcidin mimetic. Protagonist Therapeutics, Inc. is based in Milpitas, United States. “

Prudential Public (NYSE:PUK) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “PRUDENTIAL PLC provides retail financial products and services and fund management to many millions of customers worldwide. Their commitment to the shareholders who own Prudential is to maximise the value over time of their investment. They do this by investing for the long term to develop and bring out the best in their people and their businesses to produce superior products and services, and hence superior financial returns. Their aim is to deliver top quartile performance among their international peer group in terms of total shareholder returns. “

Cowen Inc initiated coverage on shares of STMicroelectronics (NYSE:STM). Cowen Inc issued an outperform rating and a $21.00 target price on the stock.

Takkt (ETR:TTK) was given a €20.00 ($23.26) price target by analysts at Berenberg Bank. The firm currently has a buy rating on the stock.

Cimarex Energy (NYSE:XEC) had its target price increased by Imperial Capital from $79.00 to $83.00. They currently have an outperform rating on the stock.

Receive News & Ratings for Agilent Technologies Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies Inc and related companies with MarketBeat.com's FREE daily email newsletter.



Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit